Member Info for KilkennyTed

The covid stocks are getting a battering, some rightly so as they have produced nothing yet & are overpriced. Ncyt on the other hand have brought product to market, debt free & cash in the bank. I'm as baffled a as anyone with the consistent drop in price since beginning of May. A very Hostile environment. Time to put the tin hat on & sit in the trenches. Once the smoke clears we'll have a better view of the battlefield.

Very interesting read Borsaci06. Thanks for posting.

Seadoc.
I think it was the same test as the White House. Someone said to Trump "Spit on your finger yo u prick"

True or false it's moving on up.

Neil13
I thought you had gone. Buy bye

The biotech company at the heart of government attempts to rapidly increase coronavirus testing has forecast that significant demand could remain into next year.
Yesterday, alongside its annual results, Novacyt said that its board believed demand for its Covid-19 diagnostic test “will continue through to the end of the year, and may extend well into 2021”.
Novacyt said that in the four months to the end of April, its earnings before interest, tax, depreciation and amortisation (Ebitda) margin was more than 50 per cent.
It said: “Should the current level of activity continue for the full year, it will be financially transformational for the business and orders suggest a continuing increase in the level of sales activity.”
Novacyt has emerged as one of the key companies in the drive to speed up diagnostic testing to combat the pandemic. It is dual listed in Paris, where it is based, and on the Aim in London. Most of its operations are in Britain where it has an office and plant in Camberley, Surrey. Primerdesign, the subsidiary developing the test, is based near Southampton.
The company is supplying tests to more than 100 countries, including to the NHS in Britain, and has sold and received orders worth more than £90 million. Last month it signed a contract with the Department of Health and Social Care for 288,000 tests a week for an initial six months.
Novacyt has also teamed up with AstraZeneca and Glaxosmithkline, the country’s big drugs companies, and the University of Cambridge, to set up a testing laboratory at the university and to provide 30,000 tests a day.
Novacyt became the second company after Roche, the Swiss multinational, to have its test listed by the World Health Organisation for emergency use. It has separately been approved in more than 16 countries, including the US and India.
It has access to eight manufacturing sites, including its two sites in Britain, capable of producing more than ten million tests per month, which it expects to hit by next month.
Novacyt said that it expected to generate significant levels of cash, which at the end of April was €9.2 million, compared with €1.8 million at the end of December. It said the test had increased its global customer base and would have a “positive, long-term effect on the business” and increase interest in other products.
For the year to the end of December, Novacyt said that revenue decreased by 6 per cent to €13.1 million and Ebitda fell to €0.2 million in 2019 compared with €0.6 million in 2018.
It said that due to the “extraordinary position the company finds itself in, the financial highlights for 2019 do not have a material bearing on the current business”.
Graham Mullis, Novacyt’s chief executive, said that 2019 had been a year of consolidation as it completed a refinancing and restructuring of the business but that the current year was expected “to be transformational for the business in almost every way”.

You've hit the nail on the head. The health minister on Breakfast tv couldn't answer any specific questions as to how many have we ordered, when will they be delivered & how much do they cost. Just a Big headliner grabber like you get on the red tops. I hope they make as much fuss about ODX when we get the PHE stamp of approval.

Aye Aye Captain. Steady as she goes.

You would hope so as it is this constant selling which is holding the SP back. Which doesn't make sense as they could make a lot more money if they held off & see if it fly's.

It's for a vaccine in colab with Jenner institute
https://www.bbc.co.uk/news/business-52483359?intlink_from_url&link_location=live-reporting-story

Bramley loved your Top 10 for Today. Can't wait for tomorrow's .

Quite a few late reported trades. This being the largest
17:06:33 29-Apr-2020 55.00GBX 282,750 155,512.50 Off-book XOFF

HVivo placed the call for volunteers for a coronavirus trial on its flucamp.com site on March 4. It has received 54,000 replies. “On a normal week we might get 20 to 40 volunteers,” says Friel. Volunteers get £3,500, but Friel says the motivation is not monetary. “It’s almost like contributing to the war effort.”

Extract from article from The Times link
Open Orphan
Cathal Friel, the chairman of Open Orphan, calls hVivo his “lucky acquisition”. HVivo specialises in viral study models and testing the efficacy of vaccines. The company owns a 24-bedroom quarantine clinic in London.
The AIM-quoted Open Orphan bought hVivo “because it looked cheap”, says Friel. About £113m (€130m) has been invested in the clinic, viral testing models and a universal flu vaccine. While structured as a merger, Open Orphan in effect bought hVivo for £13m. It was an “unloved company” in an unfashionable corner of the pharma services sector, according to Friel — but not any more.
“In truth, in the past number of years there hasn’t been a lot of money spent on developing vaccines — it’s been all talk and no action,” he says. “In the past six weeks, suddenly, being a world leader in viral studies and testing has become a very interesting place.”
Last week Open Orphan announced its involvement in an antiviral treatment trial for Covid-19 with Russian pharma outfit Nearmedic International. It is in talks with eight pharma firms about using its facilities to mount a “human challenge” study on potential vaccine candidates. As such, it could play an integral part in bringing a vaccine to market quickly.
Normally, the efficacy of a vaccine candidate is tested in field studies, where the treatment and a placebo are given to thousands — or even tens of thousands — of people. Reseachers monitor those who get infected and how they react.
These phase III field studies are complex and time-consuming, and often the longest part of a vaccine’s development. With Covid-19, the focus of the health authorities and the public is to suppress the natural spread of the virus, which may frustrate the field study.
With a human challenge study, a small sample of people, perhaps 100 to 150 , are given the vaccine candidate or a placebo. All subjects are then infected with an attenuated strain of coronavirus a month later, and monitored in a quarantined environment for 10 days. Nir Eyal, director of the centre for population-level bioethics at Rutgers University in New Jersey, told Nature publication that human challenge studies could “greatly accelerate the time to approval and potential use” of a coronavirus vaccine.
The hVivo clinic has a virology laboratory and is one of only two such private facilities in Europe.
Friel said volunteers would be selected from the lowest-risk, healthiest cohorts. The clinic will have access to a full array of antiviral treatments, if necessary. “Over a three-month period, we can have 140 patients tested,” says Friel.
An ethical concern exists about challenging humans with even a weakened strain of a potentially deadly virus. Eyal says society lets “humans volunteer to do risky things” all the time. “We let people volunteer to be emergency medical services during this period. That significantly elevates their risk of getting infected.”
HVivo placed the call for vo

Here's the article from The Times for those that can't access it.
A London-listed biotechnology company at the centre of efforts to accelerate coronavirus testing has signed a contract with the Department of Health and Social Care.
From Monday Novacyt will supply 288,000 diagnostic tests per week for use in the NHS for an initial six months. There is an option to extend the agreement.
The company is already supplying more than 20 hospitals with its tests after earlier orders from Public Health England.
Novacyt’s Primerdesign subsidiary is developing the test in Southampton. This month the test became the second to be listed by the World Health Organisation as eligible for emergency use, after one produced by Roche, the Swiss multinational.
The little-known company has emerged as one of the leaders in the drive to speed up diagnostic testing to combat the pandemic, sending its shares surging as retail shareholders have piled in. They closed up 45p, or 12.2 per cent, at 415p last night. At the end of last year they were changing hands for 13p.

Matt Han****, the health secretary, has promised 100,000 daily tests by the end of the month, but testing remains below that level.
Novacyt is dual-listed in Paris, where it has its headquarters, and on Aim, London’s junior stock market. The majority of its operations are in Camberley, Surrey.
Novacyt is also supplying tests to provide data as part of a partnership agreed this month with Astrazeneca and Glaxosmithkline, the giant British companies, and the Anne McLaren Laboratory of Cambridge University. They aim to provide 30,000 tests a day by early May.
Before the WHO designation, Novacyt had already secured fast-tracked regulatory approval in countries including Britain, the United States and India.
It has been increasing its manufacturing and distribution capacity. It signed manufacturing partnership agreements with Biopharma Process Services and Biofortuna, both based in the UK, this month after reaching an agreement last month with Yourgene, an Aim-listed diagnostics company in Manchester.
It expects to double production over the next three months to about eight million tests a month.

Missed all the fun after lunch. Crazy half hour on the back of what? No official news anyway. Keep holding as this has still along way to run still.

Chester. That's the first time I've heard a slightly negative post from you. Keep the faith I'm sure the funding will be sorted. This company has a bright future in these dark times.

If you're just checking on the share price for the first time today don't believe your eyes. LSE is having a breakdown.

Wont be long then 227 paid

0.65 paid